TD Cowen Lowers Astera Labs (NASDAQ:ALAB) Price Target to $170.00

Astera Labs (NASDAQ:ALAB) had its target price cut by equities researchers at TD Cowen from $225.00 to $170.00 in a research note issued on Wednesday. The brokerage currently has a “hold” rating on the stock. TD Cowen’s price target indicates a potential downside of 5.19% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on ALAB. Zacks Research cut shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Barclays reissued an “equal weight” rating and issued a $155.00 target price on shares of Astera Labs in a report on Monday, October 20th. Jefferies Financial Group increased their target price on shares of Astera Labs from $95.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, July 22nd. Wall Street Zen raised shares of Astera Labs from a “hold” rating to a “buy” rating in a report on Monday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Astera Labs in a report on Wednesday, October 8th. Twelve investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $167.00.

Astera Labs Stock Down 6.4%

ALAB opened at $179.31 on Wednesday. Astera Labs has a twelve month low of $47.13 and a twelve month high of $262.90. The company has a 50-day simple moving average of $196.79 and a 200 day simple moving average of $138.70. The stock has a market capitalization of $29.80 billion, a price-to-earnings ratio of 320.20, a P/E/G ratio of 4.70 and a beta of 1.37.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.10. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. During the same quarter in the prior year, the business posted $0.23 earnings per share. Astera Labs’s revenue was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Sell-side analysts anticipate that Astera Labs will post 0.34 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jitendra Mohan sold 152,517 shares of the firm’s stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $170.33, for a total value of $25,978,220.61. Following the completion of the transaction, the chief executive officer owned 450,001 shares in the company, valued at $76,648,670.33. This trade represents a 25.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Truett Tate sold 100,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $171.38, for a total transaction of $17,138,000.00. Following the sale, the chief financial officer directly owned 518,996 shares of the company’s stock, valued at $88,945,534.48. This represents a 16.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,092,997 shares of company stock worth $192,231,120 over the last quarter. 12.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Astera Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Astera Labs by 29.6% during the 2nd quarter. Vanguard Group Inc. now owns 12,049,223 shares of the company’s stock valued at $1,089,491,000 after purchasing an additional 2,751,747 shares during the period. Alliancebernstein L.P. grew its position in shares of Astera Labs by 114.2% during the 1st quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company’s stock worth $501,289,000 after buying an additional 4,478,741 shares during the period. Atreides Management LP grew its position in shares of Astera Labs by 153.3% during the 1st quarter. Atreides Management LP now owns 4,652,264 shares of the company’s stock worth $277,601,000 after buying an additional 2,815,614 shares during the period. State Street Corp grew its position in shares of Astera Labs by 39.3% during the 2nd quarter. State Street Corp now owns 2,143,459 shares of the company’s stock worth $193,812,000 after buying an additional 604,363 shares during the period. Finally, Fred Alger Management LLC grew its position in shares of Astera Labs by 13.0% during the 1st quarter. Fred Alger Management LLC now owns 1,560,033 shares of the company’s stock worth $93,087,000 after buying an additional 179,638 shares during the period. Institutional investors and hedge funds own 60.47% of the company’s stock.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.